Shares of Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) were up 5.8% during mid-day trading on Wednesday . The company traded as high as $22.53 and last traded at $21.42. Approximately 41,216 shares were traded during trading, a decline of 74% from the average daily volume of 159,710 shares. The stock had previously closed at $20.24.
Wall Street Analyst Weigh In
A number of analysts have weighed in on RAPP shares. Stifel Nicolaus started coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They issued a "buy" rating and a $35.00 target price on the stock. Jefferies Financial Group initiated coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a "buy" rating and a $35.00 price objective on the stock. Finally, TD Cowen started coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They issued a "buy" rating for the company.
View Our Latest Stock Report on Rapport Therapeutics
Rapport Therapeutics Trading Up 4.7 %
The business has a fifty day moving average of $21.97.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($1.02). As a group, equities analysts anticipate that Rapport Therapeutics will post -3.46 EPS for the current year.
Insider Activity
In other news, Director James Healy purchased 44,032 shares of the stock in a transaction on Monday, July 1st. The stock was purchased at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the acquisition, the director now owns 40,851 shares in the company, valued at $1,001,666.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Institutional Trading of Rapport Therapeutics
Institutional investors have recently bought and sold shares of the company. Sandia Investment Management LP acquired a new stake in shares of Rapport Therapeutics during the 2nd quarter worth approximately $116,000. Davidson Kempner Capital Management LP acquired a new stake in Rapport Therapeutics in the second quarter worth $229,000. Squarepoint Ops LLC bought a new stake in Rapport Therapeutics in the second quarter valued at $380,000. The Manufacturers Life Insurance Company acquired a new position in shares of Rapport Therapeutics during the second quarter valued at about $1,757,000. Finally, TD Asset Management Inc bought a new position in shares of Rapport Therapeutics during the 2nd quarter worth about $2,361,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
